Suppr超能文献

珂立苏和固尔苏治疗早产儿呼吸窘迫综合征的疗效比较

Comparison efficacy of Curosurf and Survanta in preterm infants with respiratory distress syndrome.

作者信息

Mirzarahimi Mehrdad, Barak Manouchehr

机构信息

Department of Pediatrics, Faculty of Medicine, Ardabil University of Medical Science, Ardabil, Iran.

出版信息

Pak J Pharm Sci. 2018 Mar;31(2):469-472.

Abstract

This study aim was to compare the therapeutic efficacy of Curosurf and Survanta in preterm infants which were admitted into NICU. In this interventional study, 150 preterm infants divided randomly in two groups (75 in Survanta and 75 in Curosurf). Data analyzed by statistical methods in SPSS.19. The significance level was considered to be P<0.05.There were no statistically significant differences in gestational age, birth weight, mortality rate, pneumothorax, Brunch-Pulmonary Dysplasia (BPD), Intra Ventricular Hemorrhage (IVH) and the mean duration of hospitalization between two groups. But in repeating dose of Survanta group with 67.7% was higher than Curosurf group with 32.3% (p=0.043) and in mean duration of ventilation Survanta group with 8 days was lower than Curosurf group with 10.5 days (P=0.001). Results showed in treatment of RDS in preterm infants each of two groups had similar side-effects but the need for repeated doses in Curosurf group and need for ventilation in Survanta group is less than others.

摘要

本研究旨在比较珂立苏和固尔苏在入住新生儿重症监护病房(NICU)的早产儿中的治疗效果。在这项干预性研究中,150例早产儿被随机分为两组(固尔苏组75例,珂立苏组75例)。数据采用SPSS.19统计方法进行分析。显著性水平设定为P<0.05。两组在胎龄、出生体重、死亡率、气胸、支气管肺发育不良(BPD)、脑室内出血(IVH)以及平均住院时间方面均无统计学显著差异。但在重复给药方面,固尔苏组为67.7%,高于珂立苏组的32.3%(p=0.043);在平均通气时间方面,固尔苏组为8天,低于珂立苏组的10.5天(P=0.001)。结果显示,在早产儿呼吸窘迫综合征(RDS)的治疗中,两组的副作用相似,但珂立苏组的重复给药需求和固尔苏组的通气需求均低于其他情况。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验